Intuit (INTU) Momentum-Profit Evident; GW Pharmaceuticals (GWPH) Downward Abstract-Reaction

Intuit_INTU

Shares of Intuit Inc. (Nasdaq:INTU) climbed more than 8% in after-hours trading Thursday as the company delivered stronger-than-expected quarterly profit and revenue profit in its financial results

For its first quarter fiscal 2016, Intuit posted revenue of $713 million, a 17% increase year-over-year, and non-GAAP earnings per share of $0.09, compared to non-GAAP loss per share of ($0.11) in the same quarter the prior year, easily surpassing the Capital IQ Consensus Estimate of ($0.04) loss per share on revenues of $670.88 million for the period

According to its business outlook for the second quarter fiscal year 2016, Intuit expects revenue to be in a range of $880 million to $900 million and non-GAAP earnings per share to be in a range of $0.17 to $0.20. These expectations for the next quarter are also above the Capital IQ Consensus Estimate of $0.05 earnings per share on revenues of $826.69 million for the period

INTU stock finished the regular session at $97.42, up $0.80 (or +0.83%) with a total volume of 3,973,519 shares traded during the day

Intuit, which creates business and financial management solutions that simplify the business of life for small businesses, consumers and accounting professionals, has 277.31M Shares Outstanding, Market Capitalization (intraday) of $27.02B and INTU stock 52-week range is between $79.63 and $109.21 per share

*

GW_Pharmaceuticals_GWPH

GW Pharmaceuticals plc (Nasdaq:GWPH) shares touched the $78.00 mark during Thursday’s trading session to finally close at $82.30, down $5.42 (or -6.18%) after an abstract for a prospective observational study of add-on cannabidiol (GW Pharma’s Epidiolex or CBD) for drug-resistant pediatric epilepsies was posted on the American Epilepsy Society’s website

According to the conclusions of the abstract, add-on pure CBD was associated with more than 50% seizure reduction in one-third of patients at 3 months, best results were obtained in patients with Dravet syndrome, although one patient experienced a severe increase in seizure frequency.

770,658 shares of GW Pharmaceuticals exchanged hands on Thursday, representing an increase in activity of more than doubled its average volume (3m) of 303,958 shares

GW Pharmaceuticals, which engages in discovering, developing, and commercializing cannabinoid prescription medicines, has 20.89M Shares Outstanding, Market Capitalization (intraday) of $1.72B and GWPH stock one-year range is $65.28 – $133.98 per share

**

Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/